Loading…
← CockpitCompetitor Analysis › SANOFICONR.NS Sanofi Consumer Healthcare India LimitedOpen in the cockpit ↗

Sanofi Consumer Healthcare India LimitedSANOFICONR.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum laggard 13
Mkt cap
$869M
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$1.52M
20-day average traded
Fwd P/E
28.1×
forward earnings
ROIC−WACC
+57.0 pp
WACC 12.5%
Hurdle
-5 pp
Req g minus delivered
Next earnings
99 days
25 Feb 2027
Close · INR₹3,532
1D0.0%
1W-0.3%
1M+1.9%
3M-18.6%
6M-26.2%
YTD-21.9%
1Y-24.2%
ATR %3.6%
Beta0.50
52w lowhigh32.8% off high

What Sanofi Consumer Healthcare India does

Employees: 597

Sanofi Consumer Healthcare India at a glance

Size Sanofi Consumer Healthcare India (SANOFICONR.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $869M, the 644th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹3,532 on 18 Nov 2026.

Performance Over six months the shares fell 26.2%, against -22.8% for the median peer and +3.8% for the India market (cap-weighted) — 9th lowest of 19 in its peer set.

Growth Revenue grew 22.7% over the last twelve months (peer median +1.4%); the operating margin is 36.4% (peer median -0.8%).

Valuation It trades at 28.1× forward earnings against a peer median of 25.2× (4th cheapest of 7).

Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -5 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 57.0 points above its cost of capital (12.5% WACC).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 77SANOFICONR.NS 73
Six months, rebased to 100: Sanofi Consumer Healthcare India against the median of its 20 peers (local-currency closes).

Sanofi Consumer Healthcare India financials

Reported figures in INR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023
Revenue₹9.79B₹8.78B₹7.24B₹5.55B
Revenue growth—+21%+30%—
Gross profit₹5.90B₹4.55B₹3.80B₹3.04B
EBITDA₹3.70B₹3.13B₹2.75B₹2.19B
Net income₹2.80B₹2.40B₹1.81B₹1.65B
Free cash flown/a₹1.83B₹4.41B-₹4.00M
Capital expendituren/a₹76.0M₹99.0M₹40.0M
Total debtn/a₹248M₹203M₹0

Quarterly statements and history in the cockpit →

Sanofi Consumer Healthcare India competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%PHARM0061206007714521CRVS069620086450688176688621000597AKTS6885533002672595IMTX000813603229002082SANOFICONR.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Sanofi Consumer Healthcare India is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×40×PHARM6007714521069620086450688621SANOFICONR.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sanofi Consumer Healthcare India is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-40%-20%0%20%PHARM600771086450000597688553002082SANOFICONR.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sanofi Consumer Healthcare India is the large dot.

Sanofi Consumer Healthcare India competitors and peer comparison

How Sanofi Consumer Healthcare India compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sanofi Consumer Healthcare India against its 20 peers (data as of 18 Nov 2026)
MeasureSANOFICONR.NSPeer medianRank in peer set
1-month return+1.9%-11.6%2nd highest of 21
6-month return-26.2%-22.8%9th lowest of 19
Distance from 52-week high-32.8%-43.7%6th highest of 21
Revenue growth (TTM)+22.7%+1.4%4th highest of 19
Operating margin36.4%-0.8%highest of 19
Forward P/E28.1×25.2×4th cheapest of 7
Growth the price implies (Req g, 7 yrs)17.7%10.9%4th least demanding of 7
Growth delivered (Del g)+22.7%+1.7%highest of 7
Hurdle (Req g minus delivered)-4.9 pp+9.3 pp4th least demanding of 7
ROIC minus cost of capital+57.0 pp-2.9 pphighest of 15
EV / EBITDA22.0×8.8×most expensive of 6
Net debt / EBITDA-0.9×-0.3×3rd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%

Questions

Which companies are Sanofi Consumer Healthcare India's closest peers?
The cockpit's peer set: Pharming (PHARM.AS), SK Discovery (006120.KS), GuangYuYuan Chinese Herbal Medicine (600771.SS), City Therapeutics (CTY), Kaken Pharmaceutical (4521.T), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), Latigo Biotherapeutics (LTGO).
Is Sanofi Consumer Healthcare India expensive compared with its peers?
On forward p/e it trades at 28.1× against a peer median of 25.2×, 4th cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -5 pp: the price already allows for a slowdown.
How has Sanofi Consumer Healthcare India stock performed?
Over six months to 18 Nov 2026 the shares returned -26.2% against -22.8% for the median peer; over one year -24.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.